Objective Pure red cell aplasia (PRCA) is a rare clinical entity characterized by anemia due to severe suppression of erythroid precursors, where the other cell lineages in the bone marrow remain morphologically normal. A standard treatment has not yet been established for PRCA due to the rarity of this condition. Recently, however, the administration of either cyclosporine (CSP) or prednisolone (PSL) has been reported to be an effective treatment for PRCA. Methods To clarify the clinical characteristics of PRCA, 11 PRCA cases were retrospectively analyzed over a 13-year period at our institution. Since acute PRCA was found to be self-limiting, we administered the immunosuppressive treatment of CSP or PSL after providing supportive care for 4 weeks. Results The causes of PRCA were as follows: idiopathic (3), acute parvovirus infection (1), chronic parvovirus infection (3), thymic tumor (3), and end-stage renal disease with hemodialysis (1). Complete remission (CR) was achieved for 4 of the 5 patients treated with CSP, for 2 of the 3 patients with chronic parvovirus infection treated by immunoglobulin (Ig), and for all 3 patients treated with PSL. During the follow-up periods, 4 of the 11 patients relapsed. Complete remission was achieved a second time in all 4 cases by therapies that were more intensive and had longer administration periods than those provided during initial treatment. Consequently, 9 of the 11 patients were still alive (80%) after 5 years. Conclusion Depending on the cause of the PRCA, treatment with CSP, PSL, or Ig was found to be effective in most PRCA cases.
Introduction
Pure red cell aplasia (PRCA) is a rare clinical entity that causes anemia. PRCA is characterized by the severe suppression of erythroid precursors where all other cell lineages in the bone marrow remain morphologically normal (1) (2) (3) (4) . PRCA has been etiologically classified as idiopathic or of secondary origin (1) (2) (3) (4) . Secondary PRCA has a varied etiology such as infections, hematological disorders (large granular lymphocytic leukemia), or thymic tumor (1) (2) (3) (4) . A standard treatment has not yet been established for PRCA due to the rarity of this condition (1) (2) (3) (4) .
The mechanism of PRCA may be mediated by the natural killer cells that suppress erythroid lineage cells, the antibody-dependent suppression of erythroid lineage cells, or by T lymphocytes (1) (2) (3) (4) . Therefore, recent reports indicate that immunosuppressive treatments such as cyclosporine (CSP) or prednisolone (PSL) are effective in treating PRCA (1) (2) (3) (4) (5) (6) (7) (8) . We herein report the clinical characteristics and the treatment outcomes of 11 PRCA cases in our institution.
Materials and Methods
To determine the clinical characteristics and the treatment outcomes of PRCA, we retrospectively analyzed 11 patients who were diagnosed with PRCA and admitted to our institution over a 13-year period, from January 1, 1999 to December 31, 2011. These patients included 4 men and 7 women whose ages ranged from 1 to 91 years (median age, 48 years). The diagnosis of PRCA was based on the degree of the suppression of the erythroid series in the bone marrow (<5%) (1-3). The PRCA etiology was examined to tailor treatment appropriately. Thymic tumors were diagnosed by a combination of radiological and histological findings. Chronic parvovirus infections were diagnosed by a history of parvovirus infection, positive findings of parvovirus immunoglobulin (Ig)M or IgG, and the presence of parvovirus DNA. The serological markers of human immunodeficiency virus (HIV), human T-lymphotropic virus type I (HTLV-I), and other collagen diseases were negative in all cases. Additionally, our study included no cases of leukemia, as none of the patients exhibited any large granular lymphocytes (LGL) in the peripheral blood or any clonality of the T-cells based on a flowcytometric analysis. Since PRCA caused by infection or therapeutic drug use was found to be transient and self-limiting, these patients received supportive treatments such as red cell concentrate (RCC) transfusion during the first 4 weeks. However, we subsequently administered Ig or immunosuppressive treatment consisting of CSP or PSL based on the etiology of PRCA because no improvement was observed with this supportive care. The choice of treatment for PRCA patients was determined by each physician based on each patient's age, performance status (PS), organ function, and wishes. Furthermore, Ig was administered for chronic parvovirus infection-related PRCA cases at a dose of 5 g per day for 3 consecutive days. Case 4, who was diagnosed with chronic parvovirus infection and was treated with Ig, has been described in detail as a case report (9) . Case 7 has also been described in detail in a submitted case report. Complete remission (CR), partial remission (PR), and no response (NR) were defined as the achievement of normal hemoglobin (Hb) levels without transfusion, the presence of anemia without transfusion dependency, and persistent dependence on transfusions, respectively (3) (4) (5) (6) . This retrospective study was conducted in compliance with good clinical practice and the ethical principles of the Declaration of Helsinki.
Results

Clinical and physiological findings, laboratory findings, and treatment at first diagnosis
The ages of the patients at diagnosis ranged from 1 to 91 years (mean age, 48 years). The causes of PRCA were found to be idiopathic (3), parvovirus infection (4), thyroid tumor (3), and end-stage renal disease with hemodialysis (1) . The clinical manifestations of tachycardia and dyspnea were observed in the patients. The Hb levels of the patients ranged from 4.5 to 8.2 (median Hb, 5.4). The reticulocyte levels and the erythroid series of bone marrow were markedly suppressed in each patient (median reticulocyte levels, 0.1). The details of each patient at the time of diagnosis and relapse are listed in Table 1 . The patients received supportive treatment such as RCC transfusion during the first 4 weeks because PRCA caused by infection or therapeutic drug use was found to be transient and self-limiting. However, since no improvement was observed with supportive care, we administered Ig or immunosuppressive treatment consisting of CSP or PSL based on the etiology of PRCA. The choice of treatment for the PRCA patients, namely the administration of either CSP or PSL, was determined by each physician based on each patient's age, PS, organ function, and wishes. Furthermore, Ig was administered for chronic parvovirus infection-related PRCA cases at a dose of 5 g per day for 3 consecutive days.
Five cases of PRCA were treated with CSP at a dose of 4 to 5 mg/kg. The patient undergoing hemodialysis was administered CSP at a dose of 1 mg/kg. CR was attained in 4 of the 5 patients with PRCA who were treated with CSP, but RCC transfusion was required for Case 10. PRCA cases caused by parvovirus were due either to acute infection (1) or chronic infection (3). Acute parvovirus infection was found to be self-limiting, whereas chronic parvovirus infections were treated with Ig (3). CR was attained and RCC transfusion was thus not required in 2 of the 3 (67%) patients with chronic parvovirus infection who were administered Ig. The proviral DNA of the parvovirus was not detected in the peripheral blood smears of 2 CR patients with chronic parvovirus infection following Ig administraion, RCC transfusion was required for Case 5 (parvovirus). Three patients with PRCA were treated with PSL at a dose of 1-2 mg/kg, and all 3 patients attained CR. Therefore, CR was attained in 8 of the 11 studied cases. The median time from the initiation of treatment to achievement of CR was 66.5 days. The transition diagram of Hb and reticulocytes is shown in Fig. 1 . Hb recovery was observed after an increase in reticulocyte level at 4 to 6 weeks from diagnosis ( Fig. 1 ).
Clinical and physiological findings, pathological findings, and treatment at relapse
During the follow-up periods, 4 out of the 11 PRCA patients relapsed. The relapse triggers were upper respiratory infection (Cases 4 and 6) and the tapering or ceasing of maintenance treatment (Cases 7 and 11). The proviral DNA of parvovirus was repeatedly detected in the peripheral blood of the 2 patients with chronic parvovirus infection who relapsed. Treatment to achieve re-remission consisted of administration of Ig for Cases 4 and 6, CSP at a dose of 5 g/kg for Case 7, and PSL at a dose of 1 mg/kg for Case 11. Hb and reticulocytes did not recover at 4 to 6 weeks from initiation of these treatments (Fig. 2) . Therefore, we administered 2 additional courses of Ig for Cases 4 and 6 and a combined treatment consisting of CSP (5 mg/kg) and PSL (1 mg/kg) for Cases 7 and 11. These treatments resulted in the recovery of Hb after the increase in reticulocyte level (Fig. 2) . Consequently, all 4 relapsed patients achieved CR (mean duration, 126 days). We compared the differences between the initial treatment and the reremission treatment for the relapsed patients. Apparently, all 4 cases required therapies that were more intensive and administered for longer periods than those provided in the initial treatments. Following these therapies, 9 of the 11 PRCA patients were still living (80%) after 5 years. The causes of death for the remaining 2 patients were not related to their PRCA diagnosis and are reported as follows: progression of thymic tumor and intestinal hemorrhage due to amyloidosis during long-term hemodialysis (17 years).
Discussion
We have presented the detailed clinical characteristics and treatment outcomes for 11 PRCA patients through our experience regarding the extremely rare and recurrent nature of PRCA. These case-oriented studies should be helpful to the physicians who directly care for PRCA patients, and may provide a future direction for more efficient treatment modality. In our retrospective study, we have determined that therapeutic options such as Ig, CSP, and PSL are safe, effective, and feasible for the treatment of most PRCA patients when administered based on the etiology of the PRCA. Furthermore, maintenance treatment may be essential for preventing PRCA relapse and the re-remission therapy at relapse may require treatment that is more intensive than the initial treatment. Previous reviews have reported that for patients with primary or secondary PRCA, the efficacies of PSL, CSP, and cyclophosphamide (CPA) were almost equal at 30 to 62%, 65 to 87%, and 7 to 20%, respectively (3, 4) . However, the feasibility of long-term maintenance and cumulative side effects remain serious problems due to the recurrent nature of acquired PRCA (3, 4) .
Our initial treatments consisting of Ig, PSL, or CSP successfully achieved CR in most PRCA patients, which is consistent with the findings of previous reports. Our results suggest that Ig treatment for chronic parvovirus infection in non-immunocompetent patients was a specific treatment based on the etiology. In our patients, adverse effects during immunosuppressive treatments were recurrent herpes infection and recurrent severe pneumonia in Good's syndrome with hypogammaglobulinemia. For 2 patients, the prophylactic administration of valacyclovir or regular monthly administration of Ig was essential for controlling recurrent herpes infection and pneumonia. Moreover, for another 2 patients who were dependent on RCC transfusion, deferasirox was administered under the control of ferritin (<1,000) without development of hemochromatosis.
Thymic tumors, chronic infections, and idiopathic causes were the main causes of PRCA in our institution. Surprisingly, chronic parvovirus infections occurred in 3 nonimmunocompetent patients without HIV infection, HTLV-I infection, or a collagen disease, even though previous reports have only shown the development of chronic parvovirus infection in immunocompetent patients undergoing treatment for HIV, malignancy, or transplants (3, 4, 10) . Treatment with Ig may improve the anemia associated with PRCA and concurrently treat the parvovirus infection due to the antiviral properties of the Ig. However, the relapse of anemia was observed in 2 of the 3 patients with reactivation of parvovirus, a common occurrence with persistent parvovirus infections. Recurrent activation of the parvovirus infection may indicate that these patients did not eliminate the parvovirus infection by immunemechanism. Our findings suggest that examination for parvovirus infection is required in non-immunocompetent PRCA patients.
Previous reports suggest that the 2 mechanisms of thymoma-associated PRCA are the presence of autoaggressive T-cell clones or thymectomy itself (3, 4, 6) . In our study, 2 of the 3 thymic tumor patients did develop PRCA after thymectomy, thus suggesting that the thymectomy itself does not prevent the development of PRCA.
Regarding maintenance and re-remission treatment, our results suggest that insufficient maintenance treatment resulted in the relapse of PRCA and that re-remission treatment required therapies that were more intensive and had longer administration periods than those provided during the initial treatment. There is currently no consensus regarding CSP maintenance treatment for PRCA patients due to the recurrent nature of PRCA (1-3). In Japanese patients who maintained their first remission for more than 24 months, the reported mean maintenance dose of CSP was 2.2±0.8 mg/kg per day with a range of 1.1-3.8 mg/kg per day, or 40% of the initial dose (3, 4) . Therefore, we selected CSP for maintenance therapy at a dose of 40% of the initial dose. Consequently, and consistent with previous reports (3, 4), relapse has not occurred while patients were under the sufficient maintenance therapy.
In conclusion, treatment with CSP, PSL, or Ig was found to be effective in most PRCA cases when administered according to the etiology of the PRCA. Moreover, maintenance treatment may be crucial for preventing PRCA relapse. Further study of such cases is essential to clarify the etiology, pathogenesis, and standard treatment for PRCA.
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